MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-023-01940-x

Медицинская библиотека · Leukemia · 2023

MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Mazzera Laura, Abeltino Manuela, Lombardi Guerino, Cantoni Anna Maria, Jottini Stefano, Corradi Attilio, Ricca Micaela, Rossetti Elena, Armando Federico, Peli Angelo, Ferrari Anna, Martinelli Giovanni, Scupoli Maria Teresa, Visco Carlo, Bonifacio Massimiliano, Ripamonti Alessia, Gambacorti-Passerini Carlo, Bonati Antonio, Perris Roberto, Lunghi Paolo

СтатьяПоддержка исследования: вне правительства СШАОтозванная публикацияПеревод пока не подготовлен
Источник пометил публикацию как отозванную.

Аннотация

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR's tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1/2 induces dissociation of the pentameric MEK1/2/BCR::ABL1/BCR/ABL1 complex and causes a concurrent BCRY360/Y177, BCR::ABL1Y360/Y177 and cytoplasmic ABL1Y412/T735 dephosphorylation thereby provoking the rescue of the BCR's anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1/2-inhibitors/ATO combination for the treatment of TKI-resistant leukemia.

Для цитирования: Mazzera Laura, Abeltino Manuela, Lombardi Guerino, Cantoni Anna Maria, Jottini Stefano, Corradi Attilio, Ricca Micaela, Rossetti Elena, Armando Federico, Peli Angelo, Ferrari Anna, Martinelli Giovanni, Scupoli Maria Teresa, Visco Carlo, Bonifacio Massimiliano, Ripamonti Alessia, Gambacorti-Passerini Carlo, Bonati Antonio, Perris Roberto, Lunghi Paolo. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.. Leukemia. 2023. DOI: 10.1038/s41375-023-01940-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.